Croient Pharma Profile
Key Indicators
- Authorised Capital ₹ 4.50 M
as on 30-06-2024
- Paid Up Capital ₹ 4.05 M
as on 30-06-2024
- Company Age 12 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 120.50 M
as on 30-06-2024
- Satisfied Charges ₹ 31.00 M
as on 30-06-2024
- Revenue 7.50%
(FY 2023)
- Profit 6.95%
(FY 2023)
- Ebitda -17.73%
(FY 2023)
- Net Worth 30.11%
(FY 2023)
- Total Assets 29.27%
(FY 2023)
About Croient Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 4.50 M and a paid-up capital of Rs 4.05 M.
The company currently has active open charges totaling ₹12.05 Cr. The company has closed loans amounting to ₹3.10 Cr, as per Ministry of Corporate Affairs (MCA) records.
Dinesh Sawant, Pawankumar Ankalkope, and Shrikant Rane serve as directors at the Company.
- CIN/LLPIN
U24233MH2012PTC226900
- Company No.
226900
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Feb 2012
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Croient Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Dinesh Sawant  | Director | 14-Feb-2012 | Current |
| Pawankumar Ankalkope | Director | 14-Feb-2012 | Current |
| Shrikant Rane | Director | 14-Feb-2012 | Current |
Financial Performance and Corporate Structure Insights of Croient Pharma.
Croient Pharma Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 7.5% increase. The company also saw a slight improvement in profitability, with a 6.95% increase in profit. The company's net worth Soared by an impressive increase of 30.11%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Croient Pharma?
Unlock access to Croient Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Ransaw Remedies Private Limited
Active 3 years 11 monthsDinesh Sawant and Shrikant Rane are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 04 Jul 2023 | ₹6.25 Cr | Open |
Others Creation Date: 12 Jun 2023 | ₹8.00 M | Open |
Others Creation Date: 30 Jul 2019 | ₹5.00 Cr | Open |
How Many Employees Work at Croient Pharma?
Unlock and access historical data on people associated with Croient Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Croient Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Croient Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
